BIA 28-6156, a small-molecule therapy developed by Bial for GBA-related Parkinson’s disease, did not slow disease progression in a Phase 2 clinical trial involving people with mutations in the GBA1 gene, and the company decided to discontinue its development for the condition. Bial said that while the study…
News
A comprehensive review of the scientific literature identified more than 100 distinct ways in which off episodes affect people with Parkinson’s disease, highlighting a multifaceted burden that extends beyond movement symptoms to include cognitive, emotional, and quality-of-life impacts. The research was presented by Merz Therapeutics, the company that…
Foresee Pharmaceuticals’ oral therapy mirivadelgat has been selected to enter the Phase 2a SLEIPNIR platform trial, which is testing several experimental treatments for Parkinson’s disease. The trial, funded by Cure Parkinson’s and conducted in collaboration with Haukeland University Hospital in Bergen, Norway, is evaluating multiple therapeutic candidates…
Fecal microbiota transplantation (FMT), a technique for replacing gut bacteria, may help with gastrointestinal symptoms of Parkinson’s disease, particularly constipation, according to a review study. While the technique was found to be generally safe and beneficial for gastrointestinal symptoms in Parkinson’s disease, “at this stage, there is no convincing…
People with Parkinson’s disease who switched to the approved oral therapy Crexont, an extended-release formulation of carbidopa and levodopa, from other levodopa-based treatments gained about three additional hours of daily good on time — when symptoms are well-controlled — while also experiencing less off time, or periods…
Levodopa, a standard treatment for Parkinson’s disease, can cause uncontrolled movements called dyskinesia — and this side effect may be driven by changes in a specific receptor component in certain brain cells, a new study shows. Scientists found that an experimental gene therapy…
Montara Therapeutics received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a Parkinson’s disease treatment designed to work primarily in the brain and minimize effects on the rest of the body. The new drug will target the mTOR biological pathway.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded Lysoway Therapeutics $3.4 million in funding to support the development of an investigational therapy targeting the TMEM175 protein. The grant is part of the foundation’s Parkinson’s Disease Therapeutics Pipeline Program, which aims to accelerate the development of potential…
More than 2,000 potential participants have been identified for screening in a Parkinson’s clinical trial, thanks to the Parkinson’s Foundation‘s PD Trial Navigator matching program. The Phase 2 trial (NCT06680830), known as NEULARK, is evaluating Neuron23‘s experimental therapy, NEU-411, in up to 150 people with early-stage,…
Patient enrollment has started in a Phase 2a clinical trial evaluating Jotrol, an oral formulation of resveratrol developed by Jupiter Neurosciences as a treatment for Parkinson’s disease, the company has announced. The RESET trial (NCT07592767) is recruiting up to 30 patients at three sites in…
Recent Posts
- Tablet games may help assess thinking and memory problems in Parkinson’s
- Pondering the importance of routines for my dad, who has Parkinson’s
- Blood markers may help predict dementia risk in Parkinson’s disease
- How a sporting goods employee made my uncle feel seen
- Once-daily therapy eases early Parkinson’s symptoms in Phase 3 trial